Teleflex Closes OEM Sale, Sets Debt and Buyback Plans
The transaction generated estimated after-tax proceeds of about $1.25 billion.
Teleflex Incorporated (TFX), the medical-technology company, completed the cash divestiture of its OEM business as it reshaped its portfolio and capital structure.
The closing marked an acceleration of Teleflex’s divestiture program. The company previously expected two strategic sales to close in the second half of 2026 and generate combined after-tax proceeds of about $1.8 billion.
Teleflex sold the OEM business for $1.5 billion in cash. The company planned to direct the proceeds toward debt reduction and share repurchases.
The company allocated $800 million to debt repayment and said it would complete its $1 billion share-repurchase authorization. That plan advanced from its first-quarter disclosure, when Teleflex said opportunistic open-market repurchases would begin in the second quarter.
Teleflex deferred revised 2026 financial guidance until its Aug. 6 second-quarter report. Its prior outlook called for GAAP revenue growth of 14.4% to 15.4% and pro forma adjusted constant-currency growth of 4.5% to 5.5%.
The previous forecast also projected GAAP earnings of $2.90 to $3.20 a share and adjusted earnings of $6.25 to $6.55 a share. The coming update is set to establish Teleflex’s post-divestiture earnings and revenue baseline.